WNK2 and cancer: The journal with the most articles is the International Journal of Oncology, in which most of the articles are related to combination drugs (38.46%), and Oridonin can enhance the effects of drugs such as arsenic trioxide,[70] NVP-BEZ235,[46] gemcitabine[71] and cecuximab.[72] Interestingly, the MAPK (mitogen-activated protein kinase) pathway has been mentioned several times in related articles,[71,73–75] suggesting that MAPK is an important pathway for Oridonin to inhibit cancer cells or induce apoptosis.